среда, 14 мая 2008 г.

Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Contact us to report problems with: For Publishers For Researchers For Librarians BEVACIZUMAB PLUS PACLITAXEL/CARBOPLATIN IS PREDICTED TO BE THE CLINICAL GOLD-STANDARD FOR ADVANCED OVARIAN CANCER IN 2011 SOURCE: , Volume 1, Number 1637, 2008-05-10 , pp.PUBLISHER: Key: - Free Content - New Content - Subscribed Content - Free Trial Content KEYWORDS: ; ; ; ; ; ; ; ; ; ; ; DOCUMENT TYPE: Shortmunication This feature is in beta and some links may initially be displayed as numbers instead of article titles.Any of the links will take you to the rmended articles, regardless of the display of the link.The full text article is available for purchase $34.TAX Pressing the buy now button more than once may result in multiple purchases CREDIT/DEBIT CARD INSTITUTIONAL PAYMENT ACCOUNT OR Purchase later Key: - Free Content - New Content - Subscribed Content - Free Trial Content Website 2008 Ingenta.
Read more Statin linked to sleep disruption
Get more Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia